Direct-to-Phase II SBIR Grant from NIH Awarded to Neurexis Therapeutics to Evaluate Neuroprotective Therapeutic in Stroke Preclinical Assessment Network (SPAN)
A promising approach for preventing cognitive and behavioral impairment following ischemia Aurora, CO - Neurexis Therapeutics, Incorporated, announces it has been awarded $900,000 in funding from a Direct-to-Phase II...